FAM157C: A Drug Target / Disease Biomarker (G100996541)

Target Name: FAM157C

NCBI ID: G100996541

FAM157C

Other Name(s): family with sequence similarity 157 member C | Family with sequence similarity 157 member C | Family with sequence similarity 157, member C

FAM157C: A Drug Target / Disease Biomarker

FAM157C is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has been associated with the development of certain diseases, which has led to a growing interest in studying its potential as a therapeutic target.

The FAM157C gene is located on chromosome 16 and encodes a protein known as FAM157C, which is involved in various cellular processes, including cell adhesion, migration, and survival. The FAM157C protein is composed of 214 amino acid residues and has a calculated molecular weight of 24.1 kDa.

Studies have shown that the FAM157C gene is often mutated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The most studied of these mutations is the missense mutation, which is associated with the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

The missense mutation has been shown to cause a range of symptoms, including cognitive decline, motor neuron weakness, and neurodegeneration. The severity of the symptoms can vary depending on the specific type of mutation and the severity of the disease.

In addition to its association with neurodegenerative diseases, the FAM157C gene has also been shown to be involved in the development of certain autoimmune disorders, such as rheumatoid arthritis and psoriasis. These mutations have been shown to cause autoimmune diseases by disrupting the immune response and leading to the production of antibodies that cause inflammation and damage to body tissues.

The potential drug target for FAM157C is based on its involvement in various cellular processes and its association with the development of various diseases. The FAM157C protein has been shown to play a role in the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders.

Studies have shown that inhibiting the FAM157C protein can lead to a reduction in the growth and spread of cancer cells and a reduction in the severity of neurodegenerative diseases. In addition, inhibiting the FAM157C protein has been shown to reduce the production of antibodies in individuals with rheumatoid arthritis and psoriasis.

Furthermore, the FAM157C gene has also been shown to be involved in the development of certain autoimmune disorders. By targeting the FAM157C protein, researchers have been able to treat autoimmune disorders by reducing the production of antibodies and improving the immune response.

In conclusion, the FAM157C gene has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has been associated with the development of various diseases, which has led to a growing interest in studying its potential as a therapeutic target. Further studies are needed to fully understand the role of the FAM157C protein in the development and progression of these diseases.

Protein Name: Family With Sequence Similarity 157 Member C

The "FAM157C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM157C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets